Novo Nordisk stock slides as China accepts oral Wegovy filing and sell rating hits shares
Published on 08/27/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (ISIN DK0062498333) stock came under pressure on August 27, 2026 as investors digested China’s acceptance of the company’s marketing application for its oral Wegovy obesity tablet alongside a fresh sell rating and reduced price target from a major investment bank, putting both regulatory opportunity and valuation risk in sharp relief.
China moves oral Wegovy application into review
According to a company statement cited in recent market coverage, China’s National Medical Products Administration has started to process Novo Nordisk’s application to sell Wegovy in tablet form for weight management, marking a key regulatory step for the Danish drug maker in the world’s second-largest pharmaceutical market. A Dow Jones news report dated August 27, 2026 notes that the regulator has formally accepted the marketing application for the oral version of the GLP-1 weight-loss drug.
Wegovy belongs to the GLP-1 class of medicines that mimic a natural hormone to help control appetite and lower blood sugar, and Novo Nordisk has already launched the injectable version in several major markets. The same August 27, 2026 coverage points out that Wegovy received registration approvals in countries including the United States and the United Kingdom and was launched in the United States in January, where cumulative prescription volume has exceeded 5 million, underscoring the scale of demand the company is now aiming to tap in China. German-language reporting from August 27, 2026 echoes the regulatory acceptance and highlights the therapy’s potential in a market with high obesity rates.
Sell rating and lower target weigh on Novo Nordisk stock
While the China news widens the company’s long-term obesity opportunity, market reaction on August 27, 2026 was negative after an analyst at a large European bank downgraded Novo Nordisk from hold to sell and cut the price target on the Copenhagen-listed shares to 265 Danish kroner, trimming it from a prior objective of 290 kroner. An Investing.com market note on August 27, 2026 reports that the analyst cited mixed results earlier in the month and material uncertainty ahead of the company’s upcoming capital markets day as reasons for the more cautious stance.
The same coverage indicates that Novo Nordisk stock on Nasdaq Copenhagen fell 2.4 percent during the session to trade at 297.8 Danish kroner in reaction to the downgrade, compared with a latest official close of 304.95 Danish kroner that represented a 0.93 percent decline on the prior trading day. A separate overview of intraday market data on August 27, 2026 shows the shares changing hands at 299.05 Danish kroner, down 1.93 percent on the day, while remaining 15.0 percent above the newly stated 265 Danish kroner target, illustrating how the stock still trades at a premium to that reduced valuation yardstick. A same-day summary also notes that at 304.95 Danish kroner the latest close sat slightly below the average analyst target of 310.82 kroner but well above the new 265 kroner objective.
The negative sentiment was not limited to the home-market shares. A European data overview on August 27, 2026 shows the Novo Nordisk ADR trading at 39.58 euros, down 1.74 percent on the session and 9.94 percent since the start of 2026, signaling that global investors have already experienced a notable drawdown from earlier peaks, consistent with commentary describing a roughly 70 percent stock price decline from the company’s high before the recent downdraft. That combination of drawdown and still-elevated valuation versus a fresh sell-side target helps explain why some value-oriented frameworks still classify the stock as overvalued even after the correction, with one GF Value measure cited in a same-day article putting the fair value estimate at $108.03 against a current price near $47.
Recent fundamentals and valuation backdrop
The downgrade discussion references mixed results earlier in the month, signaling that the latest quarterly or interim figures did not fully reassure the market on growth or margins in the obesity and diabetes franchises. While specific revenue or earnings numbers for the most recent quarter are not detailed in the available coverage, the context suggests that, by August 27, 2026, Novo Nordisk had already reported its most recent interim results and that these results prompted a reassessment of growth sustainability and capital-allocation plans ahead of its planned capital markets day.
One valuation-focused overview published on August 27, 2026 notes that Novo Nordisk’s current share price embeds a significant premium to certain intrinsic value models, citing the GF Value framework that estimates a fair value of $108.03 versus a contemporaneous share price of $47.19. This implies a discount of more than 56 percent versus that model’s fair value estimate, which in turn supports an argument that the stock’s long-term dividend appeal remains intact despite near-term price weakness. For investors, that kind of valuation gap between modeled fair value and observed price often represents either an opportunity if the model’s assumptions prove correct, or a warning if the market is accurately discounting future risks such as competition in GLP-1 therapies or pricing pressure in major markets.
At the same time, same-day market commentary points out that the latest close of 304.95 Danish kroner on Nasdaq Copenhagen left Novo Nordisk only slightly below the average analyst price target of 310.82 kroner, showing that consensus still sees limited upside from current levels even before factoring in the newly introduced 265 kroner target. The quantified comparison between the share price and the new target is stark: at the intraday level of 299.05 Danish kroner, the stock trades 12.9 percent above the 265 kroner target, while sitting just 3.8 percent below the average target of 310.82 kroner, an asymmetry that can make risk-reward look skewed to the downside if growth expectations in obesity or diabetes fail to materialize fully.
Obesity portfolio and oral Wegovy tablet
Novo Nordisk’s obesity portfolio is anchored by Wegovy and related semaglutide-based treatments, with the move into oral therapy providing a strategic complement to injectable regimens. As outlined in the August 27, 2026 reports, the company’s Chinese application for the Wegovy tablet is based on the OASIS phase 3 clinical program, which consists of four trials enrolling 1,300 adults who are obese or overweight with at least one weight-related comorbidity across multiple countries and regions, including China. A Chinese-language financial news brief dated August 27, 2026 describes the local submission as covering oral semaglutide tablets for long-term weight management.
For the global obesity market, the ability to offer an oral GLP-1 therapy could address patients who are reluctant to use injections, potentially expanding the addressable population and improving adherence. The Dow Jones and European reports emphasize that Wegovy has already reached cumulative prescription volumes above 5 million in the United States since its launch there in January, which provides a numerical benchmark for the kind of demand Novo Nordisk might eventually aim to replicate, in part, in China if both injectable and tablet formulations gain approval and reimbursement.
The regulatory competition landscape is intense. A health-news summary citing a Reuters dispatch on August 27, 2026 notes that Novo Nordisk, Eli Lilly, Pfizer and local firm Innovent Biologics are all vying for market share with their GLP-1 weight-loss injections in China, where the National Health Commission has warned that the proportion of overweight or obese people could exceed 65 percent by 2030. That statistic underlines the scale of the public-health challenge and the commercial opportunity in China’s obesity market, with Novo Nordisk seeking to leverage both injectable and oral semaglutide platforms to secure a meaningful slice of that growth.
Product spotlight: Wegovy tablet in China
Wegovy in tablet form is the product at the heart of Novo Nordisk’s latest China regulatory development. The oral formulation is designed to deliver the same semaglutide molecule used in injectable Wegovy but in a daily pill, potentially improving convenience for patients and differentiating the company’s offering from purely injectable competitors. The clinical data underpinning the Chinese regulatory filing comes from the OASIS global phase 3 program, which has already demonstrated weight-loss efficacy and metabolic benefits in adult patients with obesity or overweight and at least one comorbidity.
Novo Nordisk stock level and trading context
In trading on August 27, 2026, Novo Nordisk shares on Nasdaq Copenhagen were last cited at a closing price of 304.95 Danish kroner, with intraday transactions later reported around 299.05 Danish kroner during coverage of the China regulatory news and the sell-rating catalyst. That intraday level represented a 1.93 percent decline on the day and left the shares 8.06 percent lower on a year-to-date basis at that point, while still standing 15.0 percent above the newly introduced 265 Danish kroner target, highlighting that investors continue to assign a premium relative to the cautious sell-side view even after a sizable drawdown from the peak.
Fact box
Company: Novo Nordisk A/S
ISIN: DK0062498333
Ticker: NOVO.B
Exchange: Nasdaq Copenhagen
Price (as of August 27, 2026): 299.05 Danish kroner
Market cap: not specified in the available sources
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: OMX Copenhagen 25
